| In millions, except per share items | Jun-30-23 | Mar-31-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues: |
| Vycor Medical | 0.5 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.3 | 0.5 |
| NovaVision | | | 0.0 | | | | 0.0 | |
| Nova Vision | 0.0 | 0.0 | | 0.0 | 0.0 | 0.0 | | 0.0 |
| Total revenues | 0.5 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.5 |
| Revenue growth [+] | 47.2% | 15.0% | -6.7% | -33.3% | 6.1% | -6.1% | 20.4% | 101.2% |
| Vycor Medical | 55.1% | 17.2% | -3.9% | -35.4% | 9.4% | -5.9% | 20.3% | 111.1% |
| NovaVision | | | -33.7% | | | | | |
| Nova Vision | -33.4% | -8.9% | | 0.3% | -19.9% | -7.9% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.3 | 0.5 |
| Gross margin | 91.8% | 91.5% | 86.4% | 91.5% | 89.4% | 88.4% | 89.4% | 92.0% |
| Selling, general and administrative [+] | 0.3 | 0.3 | 0.3 | 0.4 | 0.3 | 0.4 | 0.4 | 0.4 |
| General and administrative | | | | | | 0.4 | | |
| Other selling, general and administrative | | | | | | | | |
| Research and development | 0.0 | 0.0 | | | | 0.0 | 0.0 | 0.0 |
| EBITDA [+] | 0.1 | 0.0 | -0.1 | -0.1 | 0.0 | -0.1 | -0.1 | 0.0 |
| EBITDA growth | -288.1% | -230.1% | 3.7% | -242.7% | -80.6% | -9.6% | -63.5% | -122.5% |
| EBITDA margin | 23.1% | 13.5% | -23.4% | -18.1% | -11.9% | -53.5% | -21.1% | 8.5% |
| Depreciation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITA | 0.1 | 0.0 | -0.1 | -0.1 | -0.1 | -0.2 | -0.1 | 0.0 |
| EBITA margin | 20.0% | 9.2% | -28.4% | -22.7% | -16.9% | -59.1% | -25.7% | 5.4% |
| Amortization of intangibles | | | | | | 0.0 | 0.0 | 0.0 |
| EBIT [+] | 0.1 | 0.0 | -0.1 | -0.1 | -0.1 | -0.2 | -0.1 | 0.0 |
| EBIT growth | -229.8% | -162.8% | -0.4% | -416.6% | -74.4% | -6.2% | -57.2% | -111.8% |
| EBIT margin | 20.0% | 9.2% | -28.4% | -22.7% | -16.9% | -60.0% | -26.6% | 4.8% |
| Interest expense | | | 0.0 | | | 0.0 | 0.0 | 0.0 |
| Interest expense | | | 0.0 | | | 0.0 | 0.0 | 0.0 |
| Other income (expense), net [+] | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
| Gain (loss) on foreign currency transactions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | 0.0 | 0.0 |
| Pre-tax income | 0.1 | 0.0 | -0.1 | -0.1 | -0.1 | -0.2 | 0.0 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 3.4% | 9.3% | | | | | 51.8% | 1094.1% |
| Earnings from continuing ops | 0.1 | -0.2 | -0.3 | -0.1 | -0.2 | -0.2 | -0.2 | 0.0 |
| Earnings from discontinued ops | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income | 0.1 | -0.2 | -0.3 | -0.1 | -0.2 | -0.2 | -0.2 | 0.0 |
| Net margin | 14.2% | -43.0% | -89.4% | -30.2% | -75.4% | -68.3% | -47.7% | -1.9% |
| |
| Basic EPS [+] | $0.00 | $0.00 | ($0.01) | $0.00 | ($0.01) | ($0.01) | ($0.01) | $0.00 |
| Growth | -169.8% | -37.9% | 67.8% | -9873.2% | -45.8% | -16.0% | -64.8% | -100.4% |
| Diluted EPS [+] | $0.00 | $0.00 | ($0.01) | $0.00 | ($0.01) | ($0.01) | ($0.01) | $0.00 |
| Growth | -160.8% | -37.9% | 67.8% | -9873.2% | -45.8% | -16.0% | -64.8% | -100.4% |
| |
| Shares outstanding (basic) [+] | 32.6 | 32.5 | 32.0 | 31.5 | 30.8 | 29.6 | 30.2 | 29.7 |
| Growth | 3.7% | 5.5% | 5.9% | 6.0% | 10.8% | 13.5% | 14.6% | 14.9% |
| Shares outstanding (diluted) [+] | 37.5 | 32.5 | 32.0 | 31.5 | 30.8 | 29.6 | 30.2 | 29.7 |
| Growth | 19.1% | 5.5% | 5.9% | 6.0% | 10.8% | 13.5% | 14.6% | 14.9% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |